Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibabradine plus beta-blocker therapy in HFrEF
jRCTs041200027Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of ivabradine in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Daily dose of beta-blocker equivalent to carvedilol at six months. Started Nov 2020; status: completed.
02
Drugs
ivabradine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on jRCTs041200027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200027.